NCT00254800 - The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2006

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

ethinyl estradiol and levonorgestrel; exenatide

Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily

DRUG

ethinyl estradiol and levonorgestrel; exenatide

Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily

DRUG

ethinyl estradiol and levonorgestrel; exenatide

Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily

Trial Locations (1)

Unknown

Research Site, Plymouth